Psyence Group

About Psyence Group

This author has not yet filled in any details.
So far Psyence Group has created 77 blog entries.
  • PSYBIO_FEATURE_40

Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment

2025-11-04T07:40:38+02:00November 3, 2025|Investor Information, Psychedelic News|

Psyence BioMed will host an exclusive investor and shareholder webinar on September 16, 2025, at 12:00 PM EST, featuring members of its Scientific Advisory Board. The session will highlight the Company’s ongoing clinical development programs and share insights into future strategic initiatives, with expert contributions from Dan Stein, Seth Feuerstein, Albert Garcia-Romeu, and Clive Ward-Able.

Read More
  • webinar for investors and shareholders on September 16, 2025

Psyence BioMed Webinar For Investors And Shareholders, Featuring Members Of Its Scientific Advisory Board.

2025-09-03T16:01:58+02:00September 3, 2025|Investor Information, Press, Psychedelic News|

Psyence BioMed will host an exclusive investor and shareholder webinar on September 16, 2025, at 12:00 PM EST, featuring members of its Scientific Advisory Board. The session will highlight the Company’s ongoing clinical development programs and share insights into future strategic initiatives, with expert contributions from Dan Stein, Seth Feuerstein, Albert Garcia-Romeu, and Clive Ward-Able.

Read More
  • _PSYBIO_FEATURE_37

H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

2025-08-28T19:09:59+02:00August 28, 2025|Press, Psychedelic News|

Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that it will present at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8–10, 2025.

Read More
  • Tony Budden - CEO PsyLabs

Insights Care Magazine – Tony Budden

2025-05-19T14:54:32+02:00May 19, 2025|Press, Psychedelic News|

Discover the future of mental health care through the eyes of Tony Budden, CEO of PsyLabs, in his thought-provoking feature in Insights Care Magazine. As a pioneer in the development of nature-derived psychedelic compounds like psilocybin and ibogaine, PsyLabs—working in close partnership with Psyence Biomed—is advancing groundbreaking solutions for substance use disorders and other mental health challenges.

Read More
  • Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

2025-04-21T08:16:12+02:00April 21, 2025|Investor Information, Press Releases, Psychedelic News|

Psyence BioMed announced today that it received a notification letter dated April 16, 2025, from the Listings Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Rule”). The Staff's determination is based on the closing bid price of the Company’s common shares being below $1.00 for 30 consecutive business days from March 5, 2025 through April 15, 2025.

Read More

Contact Info

General inquiries — info@psyencebiomed.com

Investor inquiries — ir@psyencebiomed.com

Tel: +1-416-477-1708

Address: 121 Richmond Street West, Penthouse Suite, 1300, Toronto ON M5H2K1, Canada

Sign Up For Investor Updates

Select list(s) to subscribe to

By submitting this form, you are consenting to receive marketing emails from: Psyence Group Inc, 121 Richmond Street West, Penthouse Suite, 1300, Toronto ON M5H2K1 Canada You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.
Go to Top